Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

17
Cobalt Miners News For The Month Of July 2018

2018-07-23 seekingalpha
Cobalt market news - Darton forecasts 40% growth in cobalt demand in 2018. Tony Southgate (ERG) says: "The cobalt boom is guaranteed for the next seven to 10 years."
SIE PIO CLA PANRF RIO CCZ PAN HAV MCR KBGCF CTM FCX AXE IGO VIC BAR AOU HIG PCRCF PLM.RT SNNAF FQM MCRZF BXTMF MLX PSDNF POM AYR SHERF CDU RGARF CHK MCRZY CLQ FTMDF KAT RIO RER CSSQF GMRSF CZN PGM GBLEF NZRIF RIO AZS GLCNF DLE HBNRF MEI PIONF CZI AMSLF BPLNF HMI POS AUZ RNX RTPPF GME RTNTF FQVLF AQR PTNUF FT HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF FTSSF KATFF BBBMF MLXEF OZMLF PLM CNJ AZRMF HLPCF BPL BHP OZL ARV

0
Barra Resources' dual commodity focus will deliver consistent developments this year

2018-06-14 proactiveinvestors.com.au
Barra Resources (ASX:BAR) managing director Sean Gregory speaks to Proactive Investors about the Australia-focused exploration and development company's dual commodity focus, spanning gold and battery metals.
CNJ BAR

8
Top 6 Cobalt Junior Developer Miners To Boom By 2021/2022

2018-05-17 seekingalpha - 1
Six cobalt junior developers can each produce ~5,000 tonnes pa of cobalt by 2021/22. These companies each have the potential to be worth ~AUD 3b if cobalt prices remain strong.
CLA CCZ HAV GLCNF ECSIF CZI AMSLF BPLNF POS HIG AUZ RNX RNKLF GME AQR FT PSDNF AYR AEOMF KATFF RNX.WT FTMDF KAT CNJ BPL HLPCF CSSQF

208
Cobalt Miners News For The Month Of March 2018

2018-03-25 seekingalpha - 1
Cobalt spot price news - Spot prices rise 18.7% in the past month as inventory falls. The cobalt spot price is now over USD 40/lb, and approaching USD 100,000/tonne.
SIE PIO PANRF HAV PAN KBGCF MCR FCX ECSIF IGO VIC BAR AOU HIG PLM.RT TAKRF UMICF SNNAF FQM LGI MCRZF BXTMF MLX PSDNF POM CDU RGARF CHK VLKAF MCRZY FTMDF KAT RER CSSQF GMRSF CZN PGM GBLEF NZRIF AZS GLCNF DLE HBNRF MEI PIONF CZI AMSLF HMI POS AUZ RNX GME AAPL FQVLF AQR MBL PTNUF FT HNLMF ORR CDNMD 3993 UMICY CDNMF IIDDY AEOMF USCFF KATFF MLXEF OZMLF PLM S CNJ AZRMF HLPCF BHP OZL ARV

5
Australia Mines Offers Nickel-Cobalt Exposure With Three Promising Projects In Australia

2018-03-21 seekingalpha
The Sconi resource estimate has 54,500 tonnes of contained cobalt with exploration upside. The Sconi project has recently secured 100% cobalt and nickel off-take.
FT PSDNF HAV ECSIF AEOMF CZI AMSLF KATFF POS HIG AUZ RNX FTMDF KAT GME CNJ HLPCF CSSQF AQR GMRSF

Related Articles

REPH: Recro Pharma Analysis and Research Report

20h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

21h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...